Latest Neuroblastoma Stories
An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10.
An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease.
In a genome sequencing study of 74 neuroblastoma tumors in children, scientists at the Johns Hopkins Kimmel Cancer Center and the Children's Hospital of Philadelphia (CHOP) found that patients with changes in two genes, ARID1A and ARID1B, survive only a quarter as long as patients without the changes.
In a world-first, researchers from the Australian Centre for Nanomedicine at the University of New South Wales (UNSW) in Sydney have developed a nanoparticle that could improve the effectiveness of chemotherapy for neuroblastoma by a factor of five.
After leukaemia and brain tumors, neuroblastoma is the most common form of cancer to affect children.
A whole-genome scan to identify large-scale chromosomal damage can help doctors choose the best treatment option for children with neuroblastoma, one of the most common types of childhood cancer.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.